KaydedilenlerDerginizi ekleyin

Dergiler / Avrasya Sağlık Bilimleri Dergisi / 2026 / Cilt: 7 Sayı: 1

Diyabet Tedavisinde Antioksidan Etki: Alfa Lipoik Asit

Umut Dalmış(ANKARA MEDİPOL ÜNİVERSİTESİ)0009-0007-5128-7215
Emine Merve Ekici(SAĞLIK BİLİMLERİ ÜNİVERSİTESİ, GÜLHANE SAĞLIK BİLİMLERİ FAKÜLTESİ)0000-0001-5409-6309
Sayfa
68–74
Yayın Tarihi
2024-01-29
🏛️Bu makalenin bibliyografik verileri ve tam metin bağlantısı DergiPark üzerinden sağlanmıştır.
DergiPark Kaydı ↗
✨

Yapay Zeka Hızlı Bakış & Çıkarımlar

AI Insight
⚡ TL;DR(1 Cümlede Hızlı Çıkarım)

Bu derlemede alfa lipoik asit ve diyabet arasındaki ilişkiyi değerlendirmek amaçlanmaktadır.

📌 3 Maddede Bu Makale

🎯
Amaç & Hipotez:Alfa lipoik asit besinlerde bulunmasının yanı sıra vücutta da sentezlenebilen bir maddedir.
📊
Temel Bulgular & Veri:Ağır metaller ile şelat oluşturarak vücuttaki toksin etkilerini azaltabilir.
💡
Sonuç & Katkı:Bu derlemede alfa lipoik asit ve diyabet arasındaki ilişkiyi değerlendirmek amaçlanmaktadır.
🔬Tür:Literatür & Derleme Çalışması
📍Kapsam:Genişletilmiş Akademik Örneklem
⚙️Değişkenler:Diyabet · alfa lipoik asit · antioksidan

Özet

Alfa lipoik asit besinlerde bulunmasının yanı sıra vücutta da sentezlenebilen bir maddedir. Alfa lipoik asit hem suda hem de yağda çözünebilen tek antioksidan olup ve glutatyon, C ve E vitamini gibi diğer antioksidanların yeniden kullanılmasını sağlamaktadır. Hem kendisi hem de indirgenmiş formu olan dihidrolipoik asit antioksidan özellik gösterir. Ağır metaller ile şelat oluşturarak vücuttaki toksin etkilerini azaltabilir. Ayıca insülin sinyal yolaklarında yer almaktadır. Bu özellikleri sayesinde önemli bir antioksidan olarak kabul edilmektedir. Günümüzde artan kronik hastalıklardan birisi olan diyabet ve diyabetin komplikasyonlarını azaltmaya yönelik çeşitli çalışmalar yapılmaktadır. Bu derlemede alfa lipoik asit ve diyabet arasındaki ilişkiyi değerlendirmek amaçlanmaktadır.

🔖

Bu Makaleye Atıf Yap

Dalmış, U., Ekici, E. M. (2024). Diyabet Tedavisinde Antioksidan Etki: Alfa Lipoik Asit. Avrasya Sağlık Bilimleri Dergisi, Cilt: 7 Sayı: 1, 68–74. https://doi.org/10.53493/avrasyasbd.1344385

📄 Tam Metin PDF Okuyucu

📄

PDF görüntüleyici hazırlanıyor...

Kaynakça (38)

  1. Agathos E, Tentolouris A, Eleftheriadou I, Katsaouni P, Nemtzas I, Petrou A. (2018). Effect of α-lipoic acid on symptoms and quality of life in patients with painful diabetic neuropathy. J Int Med Res., 46(5):1779-1790.
  2. Allison S. Fragakis C. Popular dietary supplements, Faulhaber D. (ed), 3 bsk., 0880913630, United States of America. Baysal A, Aksoy M, Besler T, Bozkurt N, Keçecioğlu S, Mercanlıgil S. (2014). Diyet El Kitabı, Baysal A. (Ed), 13 bsk., Hatiboğlu, Ankara.
  3. Billgren E, Cicchillo R, Nesbitt M, Booker. (2010). Lipoic Acid Biosynthesis and Enzymology, Mander, L., Liu, H.W. Comprehensive natural products ıı: chemistry and biology. 9(1):181-212.
  4. Calabrese EJ, Agathokleous E, Dhawan G, Kapoor R, Calabrese V. (2023). Protective effects of alpha lipoic acid (ALA) are mediated by hormetic mechanisms. Food and Chemical Toxicology. 177:113805.
  5. Dan Z, Low PA, Litchy WJ, Boulton AJ, Vinik AI, Freeman R, Samigullin R, Tritschler H, Munzel U, Maus J, Schütte K, Dyck PJ. (2011). Efficacy and Safety of Antioxidant Treatment With α-Lipoic Acid Over 4 Years in Diabetic Polyneuropathy: The NATHAN 1 trial. Diabetes Care, 34(9):2054-2060.
  6. Didangelos T, Karlafti E, Kotzakioulafi E, Kontoninas Z, Margaritidis C, Giannoulaki P, Kantartzis K. (2020). Efficacy and Safety of the Combination of Superoxide Dismutase, Alpha Lipoic Acid, Vitamin B12, and Carnitine for 12 Months in Patients with Diabetic Neuropathy. Nutrients, 12(11):3254.
  7. Dünya Sağlık Örgütü, (Erişim Tarihi:18 temmuz 2023). https:// www.who.int/health-topics/diabetes#tab=tab_1.
  8. ElSayed NA, Aleppo G, Aroda VR, Bannuru RR, Brown FM, Bruemmer D, Collins BS, Hilliard ME, Isaacs D, Johnson EL, Kahan S, Khunti K, Leon J, Lyons SK, Perry ML, Prahalad P, Pratley RE, Seley JJ, Stanton RC, Gabbay RA. (2023). 3. Prevention or Delay of Type 2 Diabetes and Associated Comorbidities: Standards of Care in Diabetes. Diabetes Care, 46:41-8.
  9. Esposito C, Ugo Garzarella E, Santarcangelo C, Di Minno A, Dacrema M, Sacchi R, Piccinocchi G, Piccinocchi R, Daglia M. (2021). Safety and efficacy of alpha-lipoic acid oral supplementation in the reduction of pain with unknown etiology: A monocentric, randomized, double-blind, placebo-controlled clinical trial. Biomedicine & Pharmacotherapy, 144:112308.
  10. Freeland RO. (1951). The Green Pigment and Physiology of Guard Cells. Science, 114(2952):94-95.
  11. Golbidi S, Badran M, Laher I. (2011). Diabetes and Alpha Lipoic Acid. Front Pharmacol. Frontiers in Pharmacology, 2:69.
  12. Gomes MB, Negrato CA. (2014). Alpha-lipoic acid as a pleiotropic compound with potential therapeutic use in diabetes and other chronic diseases. Metabolic Syndrome, 28;6(1):80.
  13. Gosselin L, Chrapowitzky L, Rideout TC. (2019) Metabolic effects of α-lipoic acid supplementation in pre-diabetics: a randomized, placebo-controlled pilot study. Food Funct, 10(9):5732-5738.
  14. Gregory M, Moore DJ, Simmons H. (2013). Type 1 Diabetes Mellitus. Pediatrics in Review, 34(5):203-215.
  15. Hamid D, Nienaa YA, Mostafa TM. (2022). Alpha-lipoic acid improved anemia, erythropoietin resistance, maintained glycemic control, and reduced cardiovascular risk in diabetic patients on hemodialysis: a multi-center prospective randomized controlled study.Eur Rev Med Pharmacol Sci, 26(7):2313-2329.
  16. Hassan BH, Cronan JE. (2011). Protein-Protein Interactions in Assembly of Lipoic Acid on the 2-Oxoacid Dehydrogenases of Aerobic Metabolism. Journal of Biological Chemistry, 286(10):8263-8276.
  17. Hermann R, Uchida R, Okamoto H, Ikuta N, Terao K, Hirota T. (1996). Enantioselective pharmacokinetics and bioavailability of different racemic alpha lipoic acid formulations in healthy volunteers. Eur. J. Pharm, Sci. 4:167-174.
  18. International Diabetes Federation (IDF). (2021). IDF Diabetes Atlas. Boyko E, Dianna J, Piemonte L, Riley PR, Sun H. (Ed), 10 bsk., International Diabetes Federation, Brussels.
  19. Jeffrey S, Samraj I, Raj Sundara Behin. (2021). The Role of Alpha-lipoic Acid Supplementation in the Prevention of Diabetes Complications: A Comprehensive Review of Clinical Trials, Current Diabetes Reviews, 17(9):12.
  20. Konrad, D., Somwar, R., Sweeney, G., Yaworsky, K., Hayashi, M., Ramlal, T., and Klip, A. (2001). The antihyperglycemic drug alpha-lipoic acid stimulates glucose uptake via both GLUT4 translocation and GLUT4 activation: potential role of p38 mitogen-activated protein kinase in GLUT4 activation. Diabetes 50(6): 1464-1471.
  21. Kozlov A, Staniek K, Nohl H. (1999). Dihydrolipoic acid maintains ubiquinone in the antioxidant active form by two-electron reduction of ubiquinone and one-electron reduction of ubisemiquinone. Arch Biochem Biophys, 363(1):148-154.
  22. Mandani M, Badehnoosh B, Jalali-Mashayekhi F, Tavakoli-Far B, Khosrowbeygi A. (2021). Alpha-lipoic acid supplementation effects on serum values of some oxidative stress biomarkers in women with gestational diabetes. Gynecol Endocrinol, 37(12):1111-1115.
  23. McCreight L, Bailey C, Pearson, E.R. (2016) Metformin and the gastrointestinal tract. Diabetologia, 59:426-435.
  24. Najafi N, Mehri S, Ghasemzadeh Rahbardar M, Hosseinzadeh H. (2022). Effects of alpha lipoic acid on metabolic syndrome: A comprehensive review. Phytotherapy Research, 36(6):2300-2323.
  25. Nguyen H, Gupta V. (2023). Alpha-Lipoic Acid. I. StatPearls (ed),33231971, Treasure Island, Florida.
  26. Oliveira AM, Rondó PH, Luzia LA, D’Abronzo FH, Illison VK. (2011). The effects of lipoic acid and α-tocopherol supplementation on the lipid profile and insulin sensitivity of patients with type 2 diabetes mellitus: a randomized, double-blind, placebo-controlled trial. Diabetes Res Clin Pract, 92 (2):253-260.
  27. Padmalayam I, Hasham S, Saxena U, Pillarisetti S. (2009). Lipoic Acid Synthase (LASY). Diabetes, 58(3):600-8.
  28. Papanas N, Ziegler D. (2014). Efficacy of α-lipoic acid in diabetic neuropathy. Expert Opinion on Pharmacotherapy, 15(18):2721-31.
  29. Rochette L, Ghibu S, Muresan A, Vergely C. (2015). Alpha-lipoic acid: molecular mechanisms and therapeutic potential in diabetes. Can J Physiol Pharmacol, 93(12):1021-7.
  30. Saeedi P, Petersohn I, Salpea P, Malanda B, Karuranga S, Unwin N, Colagiuri S, Guariguata L, Motala AA, Ogurtsova K, Shaw JE, Bright D, Williams R. (2019). Global and regional diabetes prevalence estimates for 2019 and projections for 2030 and 2045: Results from the International Diabetes Federation Diabetes Atlas. Diabetes Res Clin Pract, 157:107843.
  31. Salehi B, Berkay Yılmaz Y, Antika G, Boyunegmez Tumer T, Fawzi Mahomoodally M, Lobine D, Akram M, Riaz M, Capanoglu E, Sharopov F, Martins N, Cho WC, Sharifi- Rad J. (2019). Insights on the Use of α-Lipoic Acid for Therapeutic Purposes. Biomolecules, 9;9(8):356.
  32. Sievenpiper JL, Chan CB, Dworatzek PD, Freeze C, Williams S. (2018). Nutrition therapy. Can J Diabetes, 42:64-79.
  33. Uslu N, Ünsal E, Tokem Y. (2022). Amerikan Diyabet Birliği (ADA) 2022 Diyabette Tıbbi Bakım Standartları. Turkish Jurnale of Diabetes Nursing. 2(1):22.
  34. Vallianou N, Evangelopoulos A, Koutalas P. (2009). Alpha-Lipoic Acid and Diabetic Neuropathy. Rev Diabet Stud, 6(4):230-6.
  35. Won JC, Kwon HS, Moon SS, Chun SW, Kim CH, Park IB. (2020). γ-Linolenic Acid versus α-Lipoic Acid for Treating Painful Diabetic Neuropathy in Adults: A 12-Week, Double- Placebo, Randomized, Noninferiority Trial. Diabetes Metab J, 44(4):542-554.
  36. Yoshihiko I, Takeshi O, Yoko O, Tatsuo I, Yushi H. (2007). α-Lipoic Acid and Insulin Autoimmune Syndrome. Diabetes Care, 30 (9):2240–2241.
  37. Zhang YH, Wang DW, Xu SF, Zhang S, Fan YG, Yang YY, Guo SQ, Wang S, Guo T, Wang ZY, Guo C. (2018). α-Lipoic acid improves abnormal behavior by mitigation of oxidative stress, inflammation, ferroptosis, and tauopathy in P301S Tau transgenic mice. Redox Biol, 14:535-548.
  38. Nguyen H, Gupta V. (2023). Alpha-Lipoic Acid. I. StatPearls (ed),33231971, Treasure Island, Florida.